Market openNon-fractional
Cytek Biosciences/CTKB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Ticker
CTKB
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Fremont, United States
Employees
637
Website
cytekbio.com
CTKB Metrics
BasicAdvanced
$731M
Market cap
-
P/E ratio
-$0.09
EPS
1.38
Beta
-
Dividend rate
Price and volume
Market cap
$731M
Beta
1.38
Financial strength
Current ratio
6.994
Quick ratio
5.767
Long term debt to equity
2.591
Total debt to equity
3.666
Interest coverage (TTM)
-13.55%
Management effectiveness
Return on assets (TTM)
-3.06%
Return on equity (TTM)
-2.82%
Valuation
Price to revenue (TTM)
3.721
Price to book
1.87
Price to tangible book (TTM)
2.07
Price to free cash flow (TTM)
520.318
Growth
Revenue change (TTM)
20.91%
Earnings per share change (TTM)
401.90%
3-year revenue growth
26.53%
3-year earnings per share growth
-9.33%
What the Analysts think about CTKB
Analyst Ratings
Majority rating from 6 analysts.
CTKB Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$45M
-23.02%
Net income
-$6.1M
-210.91%
Profit margin
-13.61%
-244.02%
CTKB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.03
-$0.05
$0.04
-$0.05
-
Expected
$0.03
$0.03
$0.00
-$0.04
-$0.03
Surprise
-200.00%
-266.67%
1,100.12%
25.00%
-
CTKB News
AllArticlesVideos
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewsWire·1 month ago
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
GlobeNewsWire·1 month ago
Lab Instrument Industry Update - New Commercial Entrants
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytek Biosciences stock?
Cytek Biosciences (CTKB) has a market cap of $731M as of July 05, 2024.
What is the P/E ratio for Cytek Biosciences stock?
The price to earnings (P/E) ratio for Cytek Biosciences (CTKB) stock is 0 as of July 05, 2024.
Does Cytek Biosciences stock pay dividends?
No, Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Cytek Biosciences dividend payment date?
Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytek Biosciences?
Cytek Biosciences (CTKB) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Cytek Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.